(se VEL a mer)
- Sevelamer Carbonate
- Sevelamer Hydrochloride
Excipient information presented when available (limited, particularly for generics); consult specific product labeling.
Packet, Oral, as carbonate:
Renvela: 0.8 g (1 ea, 90 ea); 2.4 g (1 ea, 90 ea) [citrus flavor]
Generic: 0.8 g (1 ea, 90 ea); 2.4 g (1 ea, 90 ea)
Tablet, Oral, as carbonate:
Renvela: 800 mg
Generic: 800 mg
Tablet, Oral, as hydrochloride:
Renagel: 400 mg, 800 mg
Brand Names: U.S.
- Phosphate Binder
Sevelamer (a polymeric compound) binds phosphate within the intestinal lumen, limiting absorption and decreasing serum phosphate concentrations without altering calcium, aluminum, or bicarbonate concentrations.
Not systemically absorbed
Onset of Action
Reduction in serum phosphorus has been demonstrated after 1-2 weeks (Burke 1997; Chertow 1997).
Use: Labeled Indications
Control of serum phosphorous: Control of serum phosphorous in patients with chronic kidney disease on hemodialysis
Hypersensitivity to sevelamer or any component of the formulation; bowel obstruction
Canadian labeling: Additional contraindications (not in US labeling): Hypophosphatemia
Note: The dosing of sevelamer carbonate and sevelamer hydrochloride are similar; when switching from one product to another, the same dose (on a mg per mg basis) should be utilized.
Control of serum phosphorous: Oral:
Patients not taking a phosphate binder: Initial: 800 to 1,600 mg 3 times daily with meals; the initial dose may be based on serum phosphorous levels:
>5.5 mg/dL to <7.5 mg/dL: 800 mg 3 times daily
≥7.5 mg/dL to <9 mg/dL: 1,200 to 1,600 mg 3 times daily
≥9 mg/dL: 1,600 mg 3 times daily
Maintenance dose adjustment based on serum phosphorous concentration (goal range of 3.5 to 5.5 mg/dL; maximum dose studied was equivalent to 13 g/day [sevelamer hydrochloride] or 14 g/day [sevelamer carbonate]):
>5.5 mg/dL: Increase by 400 to 800 mg per meal at 2-week intervals
3.5 to 5.5 mg/dL: Maintain current dose
<3.5 mg/dL: Decrease by 400 to 800 mg per meal
Dosage adjustment when switching between phosphate-binder products: 667 mg of calcium acetate is equivalent to ~800 mg sevelamer (carbonate or hydrochloride)
Conversion based on dose per meal:
Calcium acetate 667 mg: Convert to 800 mg Renagel/Renvela
Calcium acetate 1,334 mg: Convert to 1,600 mg as Renagel/Renvela (800 mg tablets x 2) or 1,200 mg as Renagel (400 mg tablets x 3)
Calcium acetate 2,001 mg: Convert to 2,400 mg as Renagel/Renvela (800 mg tablets x 3) or 2,000 mg as Renagel (400 mg tablets x 5)
Refer to adult dosing.
Control of serum phosphorous: Sevelamer carbonate (Renvela): Children ≥6 years and Adolescents: Oral:
Patients not taking a phosphate binder: Initial: 800 to 1,600 mg 3 times daily with meals; dose based on body surface area:
BSA ≥0.75 to <1.2 m2: 800 mg per meal; titrate as needed by 400 mg per dose at 2 week intervals.
BSA ≥1.2 m2: 1,600 mg per meal; titrate as needed by 800 mg per dose at 2 week intervals.
Dosing: Renal Impairment
There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).
Dosing: Hepatic Impairment
There are no dosage adjustments provided in the manufacturer's labeling.
Powder for oral suspension:
Mix powder with water prior to administration. Mix the 0.8 g packet (or half of packet for 0.4 g) with 30 mL of water and mix the 2.4 g packet with 60 mL of water (multiple packets may be mixed together using the appropriate amount of water). Suspension must be consumed within 30 minutes of preparation.
As an alternative to an oral suspension in water, the contents of the packet may be pre-mixed with a small amount of food or beverage and consumed immediately (or within 30 minutes) as part of a meal. Do not heat or add to heated food or liquid.
Administer with meals.
Powder for oral suspension: May prepare an oral suspension in water using the directed amount of water appropriate for the packet size or may premix the entire content of the packet with a small amount of food or beverage (do not heat or add to heated foods or liquids).
Preparations should be consumed immediately or within 30 minutes. Oral suspension in water may need to be resuspended immediately before drinking.
Tablets: Swallow whole; do not crush, chew, or break.
Take with meals. Reduced levels of folic acid, and vitamins D, E, and K may occur; most hemodialysis patients in clinical trials received vitamin supplementation.
Store at 25°C (77°F); excursions permitted to 15°C to 30°C (59°F to 86°F). Protect from moisture.
Calcitriol (Systemic): Sevelamer may decrease the serum concentration of Calcitriol (Systemic). Monitor therapy
Cholic Acid: Sevelamer may decrease the absorption of Cholic Acid. Management: Administer cholic acid at least 1 hour before or 4 to 6 hours after administration of any bile acid-binding products, such as sevelamer, to minimize the potential for a significant interaction. Consider therapy modification
CycloSPORINE (Systemic): Sevelamer may decrease the serum concentration of CycloSPORINE (Systemic). Monitor therapy
Levothyroxine: Sevelamer may decrease the serum concentration of Levothyroxine. Management: Consider separating administration of sevelamer and levothyroxine by at least several hours whenever possible in order to decrease the risk of a significant interaction. Consider therapy modification
Mycophenolate: Sevelamer may decrease the serum concentration of Mycophenolate. Management: Administer mycophenolate at least 2 hours prior to sevelamer administration. Consider therapy modification
Quinolone Antibiotics: Sevelamer may decrease the absorption of Quinolone Antibiotics. Management: Administer oral quinolones at least 2 hours before or 6 hours after sevelamer. Exceptions: LevoFLOXacin (Oral Inhalation). Consider therapy modification
Tacrolimus (Systemic): Sevelamer may decrease the serum concentration of Tacrolimus (Systemic). Monitor therapy
Endocrine & metabolic: Metabolic acidosis (children: 34% [Pieper 2006]); adults: Frequency not defined)
Gastrointestinal: Vomiting (22%), nausea (20%), diarrhea (19%), dyspepsia (16%)
1% to 10%:
Endocrine & metabolic: Hypercalcemia (5% to 7%)
Gastrointestinal: Abdominal pain (9%), constipation (8%), flatulence (8%), peritonitis (peritoneal dialysis: 8%)
<1% (Limited to important or life-threatening): Fecal impaction, hypersensitivity reaction, intestinal obstruction (rare), intestinal perforation (rare)
Concerns related to adverse effects:
• Gastrointestinal effects: Bowel obstruction and perforation have been reported. Dysphagia and esophageal tablet retention have also been reported with the tablet formulation; consider change to suspension formulation in patients with a history of swallowing disorders
• Gastrointestinal disease: Use with caution in patients with gastrointestinal disorders including dysphagia, swallowing disorders, severe gastrointestinal motility disorders (including severe constipation), or major gastrointestinal surgery.
Concurrent drug therapy issues:
• Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions for more detailed information
• Vitamins: May cause reductions in vitamin D, E, K, or folic acid absorption.
Dosage form specific issues:
• Tablets: Should not be taken apart or chewed; broken or crushed tablets will rapidly expand in water/saliva and may be a choking hazard.
Serum chemistries, including bicarbonate and chloride
Serum calcium and phosphorus: Frequency of measurement may be dependent upon the presence and magnitude of abnormalities, the rate of progression of CKD, and the use of treatments for CKD-mineral and bone disorders (KDIGO, 2009):
CKD stage 3: Every 6-12 months
CKD stage 4: Every 3-6 months
CKD stage 5 and 5D: Every 1-3 months
Periodic 24-hour urinary calcium and phosphorus; magnesium; alkaline phosphatase every 12 months or more frequently in the presence of elevated PTH; creatinine, BUN, albumin; intact parathyroid hormone (iPTH) every 3-12 months depending on CKD severity
Pregnancy Risk Factor
Adverse events have been observed in animal reproduction studies. Sevelamer is not absorbed systemically; however, it may cause a reduction in the absorption of fat soluble vitamins and folic acid.
• Discuss specific use of drug and side effects with patient as it relates to treatment. (HCAHPS: During this hospital stay, were you given any medicine that you had not taken before? Before giving you any new medicine, how often did hospital staff tell you what the medicine was for? How often did hospital staff describe possible side effects in a way you could understand?)
• Patient may experience diarrhea or flatulence. Have patient report immediately to prescriber severe constipation, severe nausea, severe vomiting, severe abdominal pain, or dysphagia (HCAHPS).
• Educate patient about signs of a significant reaction (eg, wheezing; chest tightness; fever; itching; bad cough; blue skin color; seizures; or swelling of face, lips, tongue, or throat). Note: This is not a comprehensive list of all side effects. Patient should consult prescriber for additional questions.
Intended Use and Disclaimer: Should not be printed and given to patients. This information is intended to serve as a concise initial reference for health care professionals to use when discussing medications with a patient. You must ultimately rely on your own discretion, experience, and judgment in diagnosing, treating, and advising patients.
More about sevelamer
- Side Effects
- During Pregnancy
- Dosage Information
- Drug Interactions
- Support Group
- Pricing & Coupons
- En Español
- 7 Reviews – Add your own review/rating
- Drug class: phosphate binders